Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director now owns 19,183 shares of the company's stock, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Trading Down 1.5%

NASDAQ:XNCR traded down $0.14 during trading hours on Monday, reaching $9.05. 570,953 shares of the stock were exchanged, compared to its average volume of 667,223. Xencor, Inc. has a twelve month low of $7.16 and a twelve month high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $9.08 and a two-hundred day moving average of $14.92. The company has a market capitalization of $644.10 million, a price-to-earnings ratio of -2.83 and a beta of 0.87.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same period in the prior year, the business earned ($1.11) EPS. The business's quarterly revenue was up 104.6% on a year-over-year basis. On average, equities analysts predict that Xencor, Inc. will post -3.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on XNCR. William Blair started coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating for the company. Wells Fargo & Company dropped their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, Barclays reduced their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $28.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP boosted its position in shares of Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after acquiring an additional 1,827,883 shares in the last quarter. BVF Inc. IL increased its stake in Xencor by 169.3% in the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock valued at $52,596,000 after purchasing an additional 1,438,760 shares during the period. Braidwell LP raised its stake in Xencor by 169.0% during the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock valued at $17,617,000 after acquiring an additional 1,040,159 shares during the last quarter. Primecap Management Co. CA grew its position in Xencor by 8.6% in the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock valued at $103,857,000 after buying an additional 776,580 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its stake in shares of Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock worth $19,236,000 after acquiring an additional 685,557 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.